These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Development of Novel Anti-influenza Thiazolides with Relatively Broad-Spectrum Antiviral Potentials. Zhao L; Yan Y; Dai Q; Li X; Xu K; Zou G; Yang K; Li W; Guo X; Yang J; Li Y; Xia Q; Cao R; Zhong W Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32312780 [TBL] [Abstract][Full Text] [Related]
3. Thiazolides: a new class of antiviral drugs. Rossignol JF Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):667-74. PubMed ID: 19442032 [TBL] [Abstract][Full Text] [Related]
4. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. Rossignol JF; La Frazia S; Chiappa L; Ciucci A; Santoro MG J Biol Chem; 2009 Oct; 284(43):29798-808. PubMed ID: 19638339 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of salicylamide derivatives for combating viral infections. Xu J; Xue Y; Bolinger AA; Li J; Zhou M; Chen H; Li H; Zhou J Med Res Rev; 2023 Jul; 43(4):897-931. PubMed ID: 36905090 [TBL] [Abstract][Full Text] [Related]
6. Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro. Belardo G; Cenciarelli O; La Frazia S; Rossignol JF; Santoro MG Antimicrob Agents Chemother; 2015 Feb; 59(2):1061-9. PubMed ID: 25451059 [TBL] [Abstract][Full Text] [Related]
7. Thiazolides, a new class of antiviral agents effective against rotavirus infection, target viral morphogenesis, inhibiting viroplasm formation. La Frazia S; Ciucci A; Arnoldi F; Coira M; Gianferretti P; Angelini M; Belardo G; Burrone OR; Rossignol JF; Santoro MG J Virol; 2013 Oct; 87(20):11096-106. PubMed ID: 23926336 [TBL] [Abstract][Full Text] [Related]
8. Host-targeted nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir. Tilmanis D; Koszalka P; Barr IG; Rossignol JF; Mifsud E; Hurt AC Antiviral Res; 2020 Aug; 180():104851. PubMed ID: 32544408 [TBL] [Abstract][Full Text] [Related]
9. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. Rossignol JF J Infect Public Health; 2016; 9(3):227-30. PubMed ID: 27095301 [TBL] [Abstract][Full Text] [Related]
10. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Korba BE; Montero AB; Farrar K; Gaye K; Mukerjee S; Ayers MS; Rossignol JF Antiviral Res; 2008 Jan; 77(1):56-63. PubMed ID: 17888524 [TBL] [Abstract][Full Text] [Related]
11. The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide. Tilmanis D; van Baalen C; Oh DY; Rossignol JF; Hurt AC Antiviral Res; 2017 Nov; 147():142-148. PubMed ID: 28986103 [TBL] [Abstract][Full Text] [Related]
12. Nitazoxanide inhibits paramyxovirus replication by targeting the Fusion protein folding: role of glycoprotein-specific thiol oxidoreductase ERp57. Piacentini S; La Frazia S; Riccio A; Pedersen JZ; Topai A; Nicolotti O; Rossignol JF; Santoro MG Sci Rep; 2018 Jul; 8(1):10425. PubMed ID: 29992955 [TBL] [Abstract][Full Text] [Related]
13. Nitazoxanide Inhibits Human Norovirus Replication and Synergizes with Ribavirin by Activation of Cellular Antiviral Response. Dang W; Xu L; Ma B; Chen S; Yin Y; Chang KO; Peppelenbosch MP; Pan Q Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104275 [TBL] [Abstract][Full Text] [Related]
14. Antiviral drugs for viruses other than human immunodeficiency virus. Razonable RR Mayo Clin Proc; 2011 Oct; 86(10):1009-26. PubMed ID: 21964179 [TBL] [Abstract][Full Text] [Related]
15. Antiviral drugs in influenza: an adjunct to vaccination in some situations. Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114 [TBL] [Abstract][Full Text] [Related]
16. Second-generation nitazoxanide derivatives: thiazolides are effective inhibitors of the influenza A virus. Stachulski AV; Santoro MG; Piacentini S; Belardo G; Frazia S; Pidathala C; Row EC; Berry NG; Iqbal M; Allman SA; Semple JE; Eklov BM; O'Neill PM; Rossignol JF Future Med Chem; 2018 Apr; 10(8):851-862. PubMed ID: 29629834 [TBL] [Abstract][Full Text] [Related]
17. The second-generation thiazolide haloxanide is a potent inhibitor of avian influenza virus replication. La Frazia S; Piacentini S; Riccio A; Rossignol JF; Santoro MG Antiviral Res; 2018 Sep; 157():159-168. PubMed ID: 29908209 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and pre-clinical studies of new amino-acid ester thiazolide prodrugs. Stachulski AV; Swift K; Cooper M; Reynolds S; Norton D; Slonecker SD; Rossignol JF Eur J Med Chem; 2017 Jan; 126():154-159. PubMed ID: 27750149 [TBL] [Abstract][Full Text] [Related]
19. Oseltamivir: a review of its use in influenza. McClellan K; Perry CM Drugs; 2001; 61(2):263-83. PubMed ID: 11270942 [TBL] [Abstract][Full Text] [Related]
20. Chemical Genomics Approach Leads to the Identification of Hesperadin, an Aurora B Kinase Inhibitor, as a Broad-Spectrum Influenza Antiviral. Hu Y; Zhang J; Musharrafieh R; Hau R; Ma C; Wang J Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885544 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]